Healthcare DIVE January 14, 2025
Rebecca Pifer

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer.

Dive Brief:

  • The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers could be inflating drug costs in the U.S., in the latest and likely last salvo between antitrust regulators in the Biden administration and the controversial middlemen in the drug supply chain.
  • The report accuses CVS’ Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx of jacking up the price of lifesaving drugs by hundreds and thousands of percent. The so-called “Big Three” PBMs also directed the most profitable prescriptions to affiliated pharmacies...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
AbbVie to write off $3.5B over failed schizophrenia drug
Drug Price Negotiation Requires Oversight To Protect Older Americans
Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
Lantheus (LNTH) Acquires Life Molecular Imaging for $750M
FTC finds top 3 PBMs inflated drug prices by $7.3B

Share This Article